3-Methyl-8-amino-2,3-dihydro-1,4-phthalazindion | 861015-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-Methyl-8-amino-2,3-dihydro-1,4-phthalazindion
• 英文别名: 5-amino-2-methyl-2,3-dihydro-phthalazine-1,4-dione；5-Amino-2-methyl-2,3-dihydro-phthalazin-1,4-dion；8-amino-3-methyl-2H-phthalazine-1,4-dione
• CAS: 861015-59-0
• 化学式: C₉H₉N₃O₂
• 分子量: 191.189
• InChiKey: FNWXWBRQIICARW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  75.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Methyl-8-amino-2,3-dihydro-1,4-phthalazindion 、 2-萘酚 生成 5-(2-hydroxy-[1]naphthylazo)-2-methyl-2,3-dihydro-phthalazine-1,4-dione
  参考文献：
  名称：

  388.化学发光的有机化合物。第五部分：5-硝基-和5-氨基-邻苯二甲-1：4-二酮的甲基衍生物。与化学发光有关的结构特征

  摘要：

  DOI：

  10.1039/jr9370001841
• 作为产物：
  描述：

  3-硝基邻苯二甲酸酐 在 盐酸 、 tin 、 溶剂黄146 作用下， 生成 3-Methyl-8-amino-2,3-dihydro-1,4-phthalazindion
  参考文献：
  名称：

  Persistent, Consistent, Widespread, and Robust? Another Look at Recent Trends in Old-Age Disability

  摘要：

  Objective. The purpose of this study was to provide new evidence on disability trends among elderly persons from 1982 to 1996.Methods. The sample includes 125,949 participants aged 70 and older in the 1982-1996 National Health Interview Surveys. Logistic analysis was used to estimate the trend in disability prevalence after controlling for various sociodemographic factors.Results. We found that: (a) the prevalence of disability has declined, but the gains did not persist throughout the entire period or accelerate over time: (b) only routine care disability has declined. whereas more severe personal care disability shows no improvements; (c) estimates are robust to the exclusion of the nursing home population but may be sensitive to growth in the assisted living population: (d) estimates of decline in disability prevalence are fairly consistent across five national surveys: (e) gains have been concentrated among the most educated elderly persons: and (F) gains in education appear to be an important confounder of the improvements.Discussion. Evidence from several surveys using various measures indicate that disability has declined among elderly persons. Determining the causes of the improvements should be a high priority in future research efforts.

  DOI：

  10.1093/geronb/56.4.s206

文献信息

• PHARMACEUTICAL GRADE PHTHALAZINEDIONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：BACH PHARMA, INC

  公开号：US20160237039A1

  公开（公告）日：2016-08-18

  The present invention comprises methods of manufacturing a highly purified, pharmaceutical grade phthalazinedione for administration to a human or animal. The manufacturing methods identify and isolate starting materials, and prepare intermediate products, which are suitable for the commercial batch process production of highly purified and high-yielding intermediate products and final phthalazinedione products.

  本发明涉及制造高纯度、制药级邻苯二酮衍生物的方法，以供人类或动物使用。制造方法通过识别和分离起始材料，并制备中间产物，适用于商业批量生产高纯度和高产率的中间产物和最终邻苯二酮衍生物产品。
• Modulation of cell fates and activities by phthalazinediones
  申请人：Henry O. Mark

  公开号：US20050288291A1

  公开（公告）日：2005-12-29

  Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.

  作为细胞内氧化还原调节剂的酞嗪二酮类化合物可用于治疗细胞内氧化还原状态受损的各种疾病状态下的细胞。通过缓冲失常的氧化还原状态，酞嗪二酮类化合物能使细胞进行生存所必需的过程，并增强医疗效果。本发明的酞嗪二酮类化合物可以调节与细胞生长、分化、活性或死亡有关的功能，纠正畸变和恢复平衡，并可作为治疗各种疾病的辅助疗法。
• MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES
  申请人：Bach Pharma, Inc

  公开号：EP1924274A1

  公开（公告）日：2008-05-28
• EP1924274A4
  申请人：——

  公开号：EP1924274A4

  公开（公告）日：2008-10-08
• METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND NRF2 TRANSCRIPTION FACTORS
  申请人：Bach Pharma, Inc.

  公开号：EP2346522A1

  公开（公告）日：2011-07-27